Selecting the best-value biosimilar in emerging countries
The aim of biosimilars is to alleviate the financial burden of biological medicinal products. A most relevant challenge for emerging countries is how to select the best option available. In most cases, price is the major determinant, as budgets are chronically scarce. However, initial savings due to...
Saved in:
Main Author: | Gilberto Castañeda-Hernández |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration Publishing Inc.
2024-09-01
|
Series: | Exploration of Musculoskeletal Diseases |
Subjects: | |
Online Access: | https://www.explorationpub.com/uploads/Article/A100767/100767.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Beyond cost: a value-based framework for biosimilar procurement in emerging markets – the Thai experience
by: Anunchai Assawamakin, et al.
Published: (2025-12-01) -
BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01) -
Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01) -
Biologics and biosimilars in musculoskeletal diseases: addressing regulatory inconsistencies and clinical uncertainty
by: Lauren N. McGrath, et al.
Published: (2025-07-01) -
Modern concepts of biosimilars in hematology and oncology
by: V. V. Ptushkin
Published: (2014-07-01)